Free tool
FAERS Monitor: Catapres-Tts-3
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018891 or its brand name (Catapres-Tts-3, Clonidine). Reports on generic versions are filed under their own applications.
Reports
2,134
Serious
564
26% of reports
Hospitalization
294
Death reported
61
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- application site pruritus347
- application site erythema304
- drug ineffective280
- blood pressure increased254
- application site rash198
- product adhesion issue187
- hypertension145
- application site irritation123
- wrong technique in product usage process100
- headache96
- application site vesicles83
- blood pressure inadequately controlled83
- product quality issue83
- application site pain81
- dizziness80
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 57 |
| 2006 | 52 |
| 2007 | 157 |
| 2008 | 290 |
| 2009 | 249 |
| 2010 | 170 |
| 2011 | 95 |
| 2012 | 70 |
| 2013 | 17 |
| 2014 | 44 |
| 2015 | 54 |
| 2016 | 68 |
| 2017 | 103 |
| 2018 | 81 |
| 2019 | 110 |
| 2020 | 73 |
| 2021 | 83 |
| 2022 | 52 |
| 2023 | 62 |
| 2024 | 35 |
| 2025 | 66 |
| 2026 | 100 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,025 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site pruritusSignal | 347 | 153.1 | 138.9 | 51,527 |
| application site rashSignal | 198 | 144.0 | 126.0 | 27,585 |
| blood pressure inadequately controlledSignal | 83 | 137.9 | 111.5 | 10,991 |
| application site vesiclesSignal | 83 | 127.8 | 103.3 | 10,183 |
| application site erythemaSignal | 304 | 115.6 | 104.1 | 34,080 |
| application site irritationSignal | 123 | 98.4 | 82.8 | 11,651 |
| product adhesion issueSignal | 187 | 51.8 | 45.2 | 9,242 |
| application site painSignal | 81 | 36.4 | 29.4 | 2,744 |
| blood pressure increasedSignal | 254 | 16.4 | 14.6 | 3,678 |
| hypertensionSignal | 145 | 6.8 | 5.8 | 711 |
| product quality issueSignal | 83 | 6.0 | 4.9 | 345 |
| wrong technique in product usage processSignal | 100 | 4.9 | 4.0 | 306 |
| drug ineffectiveSignal | 280 | 2.1 | 1.9 | 170 |
| dizziness | 80 | 1.6 | 1.3 | 17 |
| headache | 96 | 1.5 | 1.2 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.